Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BDTX
BDTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BDTX News
Growth Prospects for the EGFR-NSCLC Market Analyzed
4d ago
Newsfilter
PayPal Analyst Changes Stance; Check Out Thursday's Top 5 Downgrades
Dec 04 2025
Benzinga
Black Diamond's Lung Cancer Treatment Demonstrates 60% Response Rate in Phase 2 Results
Dec 03 2025
Benzinga
US Stocks Show Varied Performance; Dollar Tree Reports Positive Earnings
Dec 03 2025
Benzinga
Black Diamond Reports 60% ORR for Silevertinib in NSCLC Patients
Dec 03 2025
Globenewswire
Black Diamond Therapeutics Reports 60% ORR for Silevertinib in NSCLC Patients
Dec 03 2025
Newsfilter
Black Diamond to Showcase Phase 2 Results of Silevertinib for Non-Small Cell Lung Cancer Today
Dec 03 2025
NASDAQ.COM
Black Diamond Therapeutics to Present Phase 2 Trial Results on December 3
Dec 02 2025
Globenewswire
Black Diamond Therapeutics to Present Phase 2 Trial Results on December 3, 2025
Dec 02 2025
Newsfilter
Stifel Confirms Buy Rating for Black Diamond Therapeutics (BDTX)
Oct 17 2025
NASDAQ.COM
Stifel Reaffirms Buy Rating for Black Diamond Therapeutics, Sets Price Target at $8
Oct 16 2025
Benzinga
Could BDTX's EGFR Inhibitor Revolutionize NSCLC Treatment?
Sep 25 2025
NASDAQ.COM
HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $10
Aug 11 2025
Benzinga
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 07 2025
Newsfilter
Raymond James Reinstates Outperform on Black Diamond Therapeutic, Announces $11 Price Target
Jul 01 2025
Benzinga
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 12 2025
Newsfilter
Show More News
